Our Science: Power & Precision
Our dual-action antibodies combine the precision of well-validated, tumor-targeting antibodies with the power of tumor-microenvironment (TME) modulators for synergistic, durable impact at the site of the tumor.
OUR VISION
To bring first-in-class treatments to people living with cancer, including those who have developed resistance to widely used first- and second-line therapies, for meaningful and durable benefit.
Immunosuppressive tumor microenvironment
Cancers deploy many defensive mechanisms to evade the immune system and the therapies that target them. Among the most effective of evasion strategies: manipulation of the complex biochemistry of the ecosystem around the tumor — the tumor microenvironment — to suppress immune cells that would otherwise attack the cancer.
Targeted therapies may initially overcome the cancer’s defenses, but the cancer will quickly develop resistance and evolve escape mechanisms.
Stimulating Immune Responses in the Tumor Microenvironment
We leverage our platform to design bifunctional molecules to precisely target the tumor and deliver the tumor-modulating payload, thereby minimizing side effects.
Effective delivery of the immune-modulating payload to the tumor can also mean that lower doses of drug are required for anti-tumor effect, resulting in less toxicity to healthy tissues elsewhere in the body.
Designed to minimize side effects
We leverage our platform to design bifunctional molecules to precisely target the tumor and deliver the tumor-modulating payload, thereby minimizing side effects.
Effective delivery of the immune-modulating payload to the tumor can also mean that lower doses of drug are required for anti-tumor effect, resulting in less toxicity to healthy tissues elsewhere in the body.